An Aptamer–siRNA Chimera Silences the Eukaryotic Elongation Factor 2 Gene and Induces Apoptosis in Cancers Expressing αvβ3 Integrin

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Nucleic Acid Therapeutics

• Publication date

  2013-05-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/nat.2012.0408PMID 23544955
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differences in integrin expression and signaling within human breast cancer cells

  2011cited by this paper
• Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.

  2011cited by this paper
• Inhibition of Cell Proliferation by an Anti-EGFR Aptamer

  2011cited by this paper
• Integrin Targeted Delivery of Chemotherapeutics

  2011cited by this paper
• Silencing or stimulation? siRNA delivery and the immune system.

  2011cited by this paper
• Eukaryotic elongation factor‐2 (eEF2): its regulation and peptide chain elongation

  2011cited by this paper
• Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.

  2011cited by this paper
• Integrin Targeted Delivery of Radiotherapeutics

  2011cited by this paper
• An Aptamer-siRNA Chimera Suppresses HIV-1 Viral Loads and Protects from Helper CD4+ T Cell Decline in Humanized Mice

  2011cited by this paper
• Novel siRNA Delivery System to Target Podocytes In Vivo

  2010cited by this paper
• Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.

  2010cited by this paper
• Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte.

  2010cited by this paper
• Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay

  2010cited by this paper
• Layer-by-layer assembled gold nanoparticles for siRNA delivery.

  2009cited by this paper
• Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors

  2009cited by this paper
• Advances in Systemic siRNA Delivery.

  2009cited by this paper
• Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells

  2009cited by this paper
• siRNA conjugate delivery systems.

  2009cited by this paper
• Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles

  2009cited by this paper
• RNAi therapeutics: an update on delivery.

  2008cited by this paper
• Integrins in prostate cancer progression.

  2008cited by this paper
• Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2.

  2008influential reference
• αvβ3 Integrin‐targeting radionuclide therapy and imaging with monomeric RGD peptide

  2008cited by this paper
• Cell Specific Aptamer–Photosensitizer Conjugates as a Molecular Tool in Photodynamic Therapy

  2008cited by this paper
• Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

  2008cited by this paper
• A pharmacoproteomic approach implicates eukaryotic elongation factor 2 kinase in ER stress-induced cell death

  2008cited by this paper
• Phototoxic aptamers selectively enter and kill epithelial cancer cells

  2008cited by this paper
• Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles

  2008cited by this paper
• Faculty Opinions recommendation of alpha v beta3 and alpha5beta1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration.

  2007cited by this paper
• Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity.

  2007cited by this paper
• αvβ3 and α5β1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration

  2007cited by this paper
• Structural basis of integrin regulation and signaling.

  2007cited by this paper
• Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides

  2006influential reference
• E-mail 陷阱

  2006cited by this paper
• Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras

  2006cited by this paper
• Type 1 Interferons and the Virus-Host Relationship: A Lesson in Détente

  2006cited by this paper
• Integrin Trafficking and the Control of Cell Migration

  2006cited by this paper
• Aptamer mediated siRNA delivery

  2006cited by this paper
• Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

  2006cited by this paper
• Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.

  2006cited by this paper
• Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival.

  2005influential reference
• Vector-based siRNA delivery strategies for high-throughput screening of novel target genes

  2005influential reference
• Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

  2005cited by this paper
• Assembly PCR oligo maker: a tool for designing oligodeoxynucleotides for constructing long DNA molecules for RNA production

  2005cited by this paper
• Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization.

  2005influential reference
• Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA

  2005cited by this paper
• Targeted inhibition of αvβ3 integrin with an RNA aptamer impairs endothelial cell growth and survival

  2005influential reference
• Protein Kinase B/Akt Acts via Glycogen Synthase Kinase 3 To Regulate Recycling of αvβ3 and α5β1 Integrins

  2004cited by this paper
• Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8

  2004cited by this paper
• Integrin signalling during tumour progression

  2004cited by this paper
• PKD1/PKCmu promotes alphavbeta3 integrin recycling and delivery to nascent focal adhesions.

  2004cited by this paper
• PKD1/PKCμ promotes αvβ3 integrin recycling and delivery to nascent focal adhesions

  2004cited by this paper
• Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

  2004cited by this paper
• RNA-mediated gene silencing

  2003cited by this paper
• Mfold web server for nucleic acid folding and hybridization prediction

  2003cited by this paper
• RNA aptamers as reversible antagonists of coagulation factor IXa

  2002cited by this paper
• Prion‐Protein‐Specific Aptamer Reduces PrPSc Formation

  2002cited by this paper
• Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.

  2001cited by this paper
• In vitro selection of the RNA aptamer against the Sialyl Lewis X and its inhibition of the cell adhesion.

  2001cited by this paper
• Studies on the expression of alpha(v)beta3 integrin receptors in non-malignant and malignant human cervical tumor tissues.

  2001cited by this paper
• Tissue factor, osteopontin, αvβ3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression

  2000cited by this paper
• Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease.

  2000cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper
• Circulating integrins: alpha 5 beta 1, alpha 6 beta 4 and Mac‐1, but not alpha 3 beta 1, alpha 4 beta 1 or LFA‐1.

  1992cited by this paper

• Advances in oligonucleotide therapeutics: recent bench-side progress in ASO, siRNA, and aptamer

  2026cites this paper
• Aptamer-mediated delivery of therapeutic oligonucleotides in glioblastoma

  2025cites this paper
• Aptamer–ODN Chimeras: Enabling Cell-Specific ODN Targeting Therapy

  2025cites this paper
• Guanidine Additive Enabled Intermolecular ortho-Phthalaldehyde-Amine-Thiol Three-Component Reactions for Modular Constructions.

  2023cites this paper
• Sensory analysis using electronic tongues

  2021cites this paper
• Advances in PSMA-targeted therapy for prostate cancer

  2021cites this paper
• Aptamer-Assisted Delivery of Nucleotides with Tumor-Suppressing Properties for Targeted Cancer Therapies

  2021cites this paper
• Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment

  2021cites this paper
• Exosomes as Natural Delivery Carriers for Programmable Therapeutic Nucleic Acid Nanoparticles (NANPs).

  2021cites this paper
• Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras

  2019cites this paper
• Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery

  2019cites this paper
• Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs

  2018cites this paper
• Targeted chimera delivery to ovarian cancer cells by heterogeneous gold magnetic nanoparticle

  2017cites this paper
• Bivalent aptamer-dual siRNA chimera is emerging as a new combination therapy

  2017cites this paper
• Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects

  2017cites this paper
• Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics.

  2016cites this paper
• Ideal and Reality: Barricade in the Delivery of Small Interfering RNA for Cancer Therapy.

  2016cites this paper
• Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer

  2016cites this paper
• IDA - ein Integrin-spezifisches DNA-Aptamer

  2016cites this paper
• Nucleic acid-based aptamers: applications, development and clinical trials.

  2015cites this paper
• Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras

  2015cites this paper
• Recent advances in siRNA delivery

  2015cites this paper
• Establishment and evaluation of a murine αvβ3-integrin-expressing cell line with increased susceptibility to Foot-and-mouth disease virus

  2015cites this paper
• Smart functional nucleic acid chimeras: Enabling tissue specific RNA targeting therapy

  2015cites this paper
• Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.

  2014cites this paper
• Integrins: players in cancer progression and targets in cancer therapy

  2014cites this paper
• Aptamers as Drug Delivery Vehicles

  2014cites this paper
• Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras.

  2014cites this paper
• Biosafe nanoscale pharmaceutical adjuvant materials.

  2014cites this paper
• Aptamers as Both Drugs and Drug-Carriers

  2014cites this paper
• Molecular insights and oligonucleotide based targeted gene therapy against cancer

  2014cites this paper
• Nucleic Acid Aptamers: New Methods for Selection, Stabilization, and Application in Biomedical Science

  2013cites this paper
• Current progress on aptamer-targeted oligonucleotide therapeutics.

  2013cites this paper